LBVE 013

Drug Profile

LBVE 013

Alternative Names: LBVE013

Latest Information Update: 14 Oct 2016

Price : $50

At a glance

  • Originator LG Life Sciences
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pneumococcal infections

Most Recent Events

  • 08 Sep 2016 Phase-I clinical trials in Pneumococcal infections (Prevention, In volunteers) in South Korea (unspecified route) (NCT02892812)
  • 28 Aug 2015 Early research in Pneumonia in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top